QYUNS-B (02509) Signs Licensing and Collaboration Agreement with Windward Bio Subsidiary for Development and Commercialization of QX027N

Stock News2025-12-22

QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 exclusive rights to develop and commercialize QX027N globally, excluding Mainland China, Taiwan, Hong Kong SAR, and Macau SAR (the licensed territories). In return, the company or its designated affiliates (collectively referred to as the "Group") will be entitled to receive payments totaling up to $700 million, including an upfront payment, equity in Windward Bio, development and commercial milestone payments, as well as tiered royalties based on QX027N's net sales in the licensed territories. QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154764518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154764518","market":"hk","top_or_hot":-1,"title":"QYUNS-B (02509) Signs Licensing and Collaboration Agreement with Windward Bio Subsidiary for Development and Commercialization of QX027N","media":"Stock News","content":"<p>QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 exclusive rights to develop and commercialize QX027N globally, excluding Mainland China, Taiwan, Hong Kong SAR, and Macau SAR (the licensed territories). In return, the company or its designated affiliates (collectively referred to as the \"Group\") will be entitled to receive payments totaling up to $700 million, including an upfront payment, equity in Windward Bio, development and commercial milestone payments, as well as tiered royalties based on QX027N's net sales in the licensed territories. QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B (02509) Signs Licensing and Collaboration Agreement with Windward Bio Subsidiary for Development and Commercialization of QX027N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B (02509) Signs Licensing and Collaboration Agreement with Windward Bio Subsidiary for Development and Commercialization of QX027N\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-22 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 exclusive rights to develop and commercialize QX027N globally, excluding Mainland China, Taiwan, Hong Kong SAR, and Macau SAR (the licensed territories). In return, the company or its designated affiliates (collectively referred to as the \"Group\") will be entitled to receive payments totaling up to $700 million, including an upfront payment, equity in Windward Bio, development and commercial milestone payments, as well as tiered royalties based on QX027N's net sales in the licensed territories. QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1154764518","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154764518","pubTimestamp":1766362942,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"QYUNS-B(02509)与Windward Bio附属公司就QX027N的开发及商业化签署许可及合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 exclusive rights to develop and commercialize QX027N globally, excluding Mainland China, Taiwan, Hong Kong SAR, and Macau SAR (the licensed territories). In return, the company or its designated affiliates (collectively referred to as the \"Group\") will be entitled to receive payments totaling up to $700 million, including an upfront payment, equity in Windward Bio, development and commercial milestone payments, as well as tiered royalties based on QX027N's net sales in the licensed territories. QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154764518","isCrawlerRequest":true}